AMRN logo

Amarin (AMRN) Stock

Profile

Sector:

Healthcare

Country:

Ireland

IPO:

01 April 1993

Indexes:

Not included

Description:

Amarin Corporation (AMRN) is a biopharmaceutical company focused on developing and commercializing innovative therapies for cardiovascular diseases. Its main product, Vascepa, is used to reduce cardiovascular risk in patients with high triglyceride levels. The company aims to improve heart health through scientific research and effective treatments.

Key Details

Price

$0.49

Annual Revenue

$306.91 M(-16.87% YoY)

Annual EPS

-$0.15(+42.31% YoY)

Annual ROE

-10.30%

Beta

1.34

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Oct 30, 2024

Recent annual earnings:

Feb 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jan 18, 2008

Analyst ratings

Recent major analysts updates

20 June '24 Cantor Fitzgerald
Overweight
18 June '24 Cantor Fitzgerald
Overweight
25 Oct '23 Jefferies
Hold
20 July '23 Goldman Sachs
Sell
19 July '23 Northland Capital Markets
Market Perform
06 Jan '23 Jefferies
Buy
19 Oct '22 SVB Leerink
Market Perform
24 May '22 Goldman Sachs
Sell
06 May '22 JP Morgan
Underweight
05 May '22 SVB Leerink
Market Perform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting
AMRN
globenewswire.com09 September 2024

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new supported and/or funded research on the clinical impact of VASCEPA®/VAZKEPA (icosapent ethyl) in patients with diabetes and high cardiovascular risk and the anti-Lp(a) oxidation mechanistic effects of eicosapentaenoic acid (EPA) will be presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting September 9 – 13, 2024 in Madrid, Spain.

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
AMRN
globenewswire.com22 August 2024

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT® cardiovascular outcomes trial with VASCEPA®/VAZKEPA® (icosapent ethyl), as well as abstracts showcasing the mechanistic activity of eicosapentaenoic acid (EPA) that will be presented at the European Society of Cardiology (ESC) Congress in London, United Kingdom, August 30 – September 2, 2024.

Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat
Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat
Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat
AMRN
zacks.com01 August 2024

Amarin's (AMRN) second-quarter 2024 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year.

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
AMRN
globenewswire.com31 July 2024

-- Cash Position of $307 Million Provides Stable and Strong Capital Foundation – -- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize VASCEPA/VAZKEPA Performance Globally -- -- Leadership Transition Completed with Appointment of Aaron Berg as President and CEO -- DUBLIN and BRIDGEWATER, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today reported financial results for the second quarter ended June 30, 2024, and provided a business update.

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
AMRN
globenewswire.com17 July 2024

-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA® in Europe --

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
AMRN
globenewswire.com17 July 2024

DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its second quarter 2024 results followed by Q&A on Wednesday, July 31st, 2024, at 8:00 a.m. ET.

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
AMRN
globenewswire.com08 July 2024

-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- -- EddingPharm Now Working to Prepare for National Reimbursement and Drug Listing (NRDL) and Enhance the Commercial Launch of VASCEPA Across Mainland China --

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok
LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok
LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok
AMRN
globenewswire.com07 June 2024

LA BOUTIQUE, the leading Thai fashion designer brand celebrated for its neo-romantic and new vintage aesthetic, is thrilled to announce the grand opening of its latest flagship store at Gaysorn Amarin LA BOUTIQUE, the leading Thai fashion designer brand celebrated for its neo-romantic and new vintage aesthetic, is thrilled to announce the grand opening of its latest flagship store at Gaysorn Amarin

Amarin Board of Directors Announces CEO Transition
Amarin Board of Directors Announces CEO Transition
Amarin Board of Directors Announces CEO Transition
AMRN
globenewswire.com04 June 2024

-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities --

Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
AMRN
Zacks Investment Research03 May 2024

Here is a comparison of the performance of Amarin (AMRN) and ANI Pharmaceuticals (ANIP) within their sector for the year to date.

FAQ

  • What is the primary business of Amarin?
  • What is the ticker symbol for Amarin?
  • Does Amarin pay dividends?
  • What sector is Amarin in?
  • What industry is Amarin in?
  • What country is Amarin based in?
  • When did Amarin go public?
  • Is Amarin in the S&P 500?
  • Is Amarin in the NASDAQ 100?
  • Is Amarin in the Dow Jones?
  • When was Amarin's last earnings report?
  • When does Amarin report earnings?
  • Should I buy Amarin stock now?

What is the primary business of Amarin?

Amarin Corporation (AMRN) is a biopharmaceutical company focused on developing and commercializing innovative therapies for cardiovascular diseases. Its main product, Vascepa, is used to reduce cardiovascular risk in patients with high triglyceride levels. The company aims to improve heart health through scientific research and effective treatments.

What is the ticker symbol for Amarin?

The ticker symbol for Amarin is NASDAQ:AMRN

Does Amarin pay dividends?

No, Amarin does not pay dividends

What sector is Amarin in?

Amarin is in the Healthcare sector

What industry is Amarin in?

Amarin is in the Drug Manufacturers - General industry

What country is Amarin based in?

Amarin is headquartered in Ireland

When did Amarin go public?

Amarin's initial public offering (IPO) was on 01 April 1993

Is Amarin in the S&P 500?

No, Amarin is not included in the S&P 500 index

Is Amarin in the NASDAQ 100?

No, Amarin is not included in the NASDAQ 100 index

Is Amarin in the Dow Jones?

No, Amarin is not included in the Dow Jones index

When was Amarin's last earnings report?

Amarin's most recent earnings report was on 30 October 2024

When does Amarin report earnings?

The next expected earnings date for Amarin is 28 February 2025

Should I buy Amarin stock now?

As of today, analysts generally recommend a 'Sell' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions